Isomorphic Labs and MSD announced on Thursday (19/11) a strategic research collaboration to discover cancer drug candidates with artificial intelligence. MSD is the trade name of Merck & Co. outside the United States and Canada.
Under the deal, Isomorphic Labs will apply its AI drug design engine, IsoDDE, to make computational predictions and deliver molecular designs against an oncology target the companies describe only as of “strategic importance” — the target was not disclosed. MSD will supply selected proprietary research datasets to feed the system, and will be responsible for preclinical and clinical development, manufacturing and commercialization of any product that comes out of the collaboration.
On the financial terms, Isomorphic Labs will receive an upfront payment from MSD, whose value was not disclosed, plus payments tied to research, development, regulatory and commercial milestones and tiered royalties on net sales. The company also has an option to co-fund development in exchange for higher royalties.
Context: the US$ 5 billion Series C
The announcement comes two days after Isomorphic Labs closed a US$ 5 billion Series C round to accelerate clinical trials of AI-designed medicines, as Geekiki reported. According to Fierce Biotech, with Merck the company now counts three of the world's four largest drugmakers by revenue among its partners.
What the partnership does not mean yet
The announcement should be kept in proportion: the work is at the early discovery stage. There is no identified drug candidate, no disclosed target and no product entering preclinical or clinical testing through this deal. Any molecule designed by IsoDDE will still have to go through MSD's full development path before becoming a medicine — a journey that takes years and may never reach the market.
Founded in 2021 and led by CEO Demis Hassabis and President Max Jaderberg, Isomorphic Labs spun out of DeepMind and built IsoDDE, a drug design engine made of foundational AI models.
MSD is the international arm of Merck & Co., headquartered in Rahway, New Jersey, and traded on the New York Stock Exchange under the ticker MRK. Isomorphic Labs is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
Featured image: Demis Hassabis, CEO of Isomorphic Labs. Photo: The Royal Society / Duncan Hull, licensed under CC BY-SA 4.0, via Wikimedia Commons.
Sources
- Merck and Isomorphic Labs Enter Strategic Research Collaboration — Business Wire (official announcement)
- Isomorphic adds Merck to AI drug discovery roster days after $5B raise — Fierce Biotech
- Merck & Co signs AI drug design deal with Isomorphic Labs days after its $5 billion raise — The Pharma Letter
Transparency: this article was produced with the assistance of artificial intelligence, based on public sources on the internet and public posts on X, including the companies' official announcement. Check the original sources listed above to confirm the details.
By Muse